| bortezomib / Generic mfg. |
ACTRN12618000913279: Cytomegalovirus-specific immune monitoring to guide pre-emptive therapy surveillance protocol for prevention of cytomegalovirus infection after renal transplantation. |
|
|
| Recruiting | 4 | 150 | | | associate Prof. Tomas Reischig, M.D., Ph.D., National Sustainability Program I [LO1503] awarded by Ministry of Education, Youth, and Physical Training of the Czech Republic, Project No. CZ.02.1.01/0.0/0.0/16_019/0000787 „Fighting INfectious Diseases“ awarded by Ministry of Education, Youth, and Physical Training of the Czech Republic, financed from The European Regional Development Fund., Charles University Research Fund [Progres Q39] | Cytomegalovirus infection after renal transplantation | | | | |
ChiCTR-OPC-15006337: Once-weekly 1.6mg/m2 bortezomib BCD regimen in elderly patients with newly diagnosed multiple myeloma who are ineligible for high-dose therapy |
|
|
| Completed | 4 | 34 | | Once-weekly 1.6mg/m2 bortezomib BCD regimen | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Committee of Science and Technology (grant no. 12ZR1416800, 13ZR1423800) | multiple myeloma | | | | |
ChiCTR-TCC-12002759: The preventive effects of amifostine on bortezomib-induced peripheral neuropathy and the underlying mechanism |
|
|
| Completed | 4 | 100 | | pretreatment with amifostine ;untreatment with amifostine | Department of Hematology, the First Affiliated Hospital of Dalian Medical University; Level of the institution：, self-funded | multiple myeloma | | | | |
2012-001813-17: A study of the reaction of the vessels and cells of patients with myeloma getting chemotherapy. |
|
|
| Ongoing | 4 | 110 | Europe | Revlimid, Cyclophosphamide, Bortezomib, Thalidomide, Dexamethasone, PL 00032/0335, EU/1/04/274/001, EU/1/08/443/001, PL0065/5045R, Revlimid, Cyclophosphamide, VELCADE, Thalidomide, Dexamethasone, Revlimid, Cyclophosphamide, VELCADE, Thalidomide, Dexamethasone | Hull and East Yorkshire Hospitals NHS Trust | Chemotherapy related thrombosis in patients treated for multiple myeloma. | | | | |
ChiCTR-IPR-16008422: Randomized controlled study of the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD) and bortezomib +thalidomide + dexamethasone (BTD) for the initial treatment of primary systemic amyloidosis (AL) |
|
|
| Recruiting | 4 | 120 | | the combination regimen of bortezomib + cyclophosphamide + dexamethasone (BCD) ;the combination regimen of bortezomib +thalidomide + dexamethasone (BTD) | People's Hospital, Beijing University; People's Hospital, Beijing University, self-paying | primary systemic amyloidosis (AL) | | | | |
2017-004003-46: A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Studio randomizzato, multicentrico, in aperto che compara due trattamenti standard, bortezomib-melfalan-prednisone (VMP) vs lenalidomide-desametasone (Rd) in pazienti non candidabili al trapianto affetti da mieloma multiplo (MM) |
|
|
| Not yet recruiting | 4 | 350 | Europe | Velcade, Melphalan, Prednisone, Lenalidomide 25 mg, Desametasone, [Velcade], [Melphalan], [Prednisone], [Lenalidomide 25 mg], [Desametasone], Powder for solution for injection, Film-coated tablet, Tablet, Capsule, hard, Oral drops, solution, VELCADE - 1 FLACONCINO DA 3.5 MG, ALKERAN - 2 MG COMPRESSE RIVESTITE CON FILM25 COMPRESSE, PREDNISONE TEVA - "5 MG COMPRESSE" 20 COMPRESSE IN BLISTER PVC-PVDC/ALU, REVLIMID - 25 MG CAPSULA RIGIDA - USO ORALE BLISTER (PCTFE/PVC/ALU) 21 CAPSULE, SOLDESAM - 0.2% GOCCE ORALI, SOLUZIONE FLACONE 10 ML | DIPARTIMENTO DI BIOTECNOLOGIE MOLECOLARI E SCIENZE PER LA SALUTE-UNIVERISITÀ DI TORINO, AIFA - Italian Medicines Agency | Newly diagnosed MM patients = 65 years old or ineligible for autologous stem cell transplant Pazienti con nuova diagnosi di MM = 65 anni o non eleggibili al trapianto autologo di cellule staminali, Newly diagnosed Multiple Myeloma patients with or older than 65 years or ineligible for autologousstem cell transplant Pazienti con nuova diagnosi di Mieloma Multiplo con et¿ superiore o uguale a 65 anni o non eleggibili al trapianto autologo di cellule staminali, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-OPC-17013860: A prospective observational study of Bortezomib, Dexamethasone and Decitabin in the treatment of recurrent / refractory multiple myeloma. |
|
|
| Not yet recruiting | 4 | 50 | | reduced dosage | Henan Cancer Hospital; Henan Cancer Hospital, without funds | Multiple Myeloma | | | | |
| Completed | 4 | 40 | | Huachansu, 4 tablets (1.2g) orally, tid ;Bortezomib combined with TD scheme | Affiliated Hospital of Nanjing University of Chinese Medicine (JiangSu Province Hospital of TCM); JiangSu Province Hospital of TCM, The First Affilated Hospital of NanJing University of TCM, Foundation of the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) | multiple myeloma | | | | |
ChiCTR-OPC-16010301: Efficacy and safety of chidamide, bortezomib and dexamethasone combination in transplant-ineligible patients with relapsed/refractory multiple myeloma: a phase 2, single center, single arm study |
|
|
| Recruiting | 4 | 80 | | bortezomib, chidamide and dexamethasone combination protocol | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Project funding | Multiple Myeloma | | | | |
2019-002626-67: EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS EVALUACIÓN DE LA EFICACIA Y SEGURIDAD DE LA COMBINACIÓN DE BORTEZOMIB, LENALIDOMIDA Y DEXAMETASONA EN PACIENTES CON MIELOMA MÚLTIPLE DE NUEVO DIAGNÓSTICO |
|
|
| Not yet recruiting | 4 | 360 | Europe | bortezomib, Revlimid, Dexamethasone, Revlimid, S02BA06, Powder and solution for solution for injection, Capsule, hard, Tablet, Velcade, Revlimid, Dexamethasone | Institut Català d'Oncologia, Institut Català d'Oncologia | Multiple myeloma Mieloma múltiple, Multiple myeloma mieloma múltiple, Diseases [C] - Cancer [C04] | | | | |
ChiCTR1900021558: Study for the efficacy and safety, the quality of life of patients and the occupational stress of doctors of RAD induction in the treatment of multiple myeloma. |
|
|
| Recruiting | 4 | 60 | | lenalidomide ;bortezomib | The First Affiliated Hospital of Sun Yat-sen University; The First Affiliated Hospital of Sun Yat-sen University, Self-raised funds | multiple myeloma | | | | |
ChiCTR1900022551: Waiting for ethics committee approval Induction therapy with bortezomib, lenalidomide, dexamethasone (VRD) in newly diagnosed multiple myeloma patients |
|
|
| Not yet recruiting | 4 | 50 | | bortezomib/lenalidomide/dexamethasone (VRD) | Peking University People's Hospital; Peking University People's Hospital, CTTQ Pharmaceutical Group Co., Ltd. | multiple myeloma | | | | |
ChiCTR2000030792: A multicenter, single-arm clinical study of bortezomib /lenalidomide /dexamethasone (VRD) regimen in newly diagnosed multiple myeloma patients |
|
|
| Recruiting | 4 | 80 | | Bortezomib /lanaduramide /dexamethasone (VRD) regimen was induced in patients with newly diagnosed multiple myeloma | Center for Cancer Prevention and Treatment, Sun Yat-Sen University; Center for Cancer Prevention and Treatment, Sun Yat-Sen University, Provided by Zhengda Tianqing Pharmaceutical Group Co. Ltd. : bortezomib for injection, product name Qianping. | Multiple myeloma | | | | |
ChiCTR1900024271: Effect of BAD regimen in patients with circulating plasma cell-positive primary diagnosis of multiple myeloma |
|
|
| Recruiting | 4 | 50 | | BAD (Bortezomib for Injection + Doxorubicin Liposome + Dexamethasone) regimen. ;BAT ((Bortezomib for Injection Dexamethasone) regimen-based three-drug regimen. | Department of Hematology, West China Hospital, Sichuan University; West China Hospital, Sichuan University, CSCO FUND OF CSPC PHARMA | Multiple myeloma | | | | |
ChiCTR-IPR-17012637: Prospective Randomized controlled study of the combination regimen of bortezomib + thalidomide + dexamethasone (VTD) and bortezomib + cyclophosphamide + dexamethasone (VCD) for the initial treatment of type AL amyloidosis |
|
|
| Not yet recruiting | 4 | 70 | | the combination regimen of bortezomib +thalidomide + dexamethasone (VTD) ;the combination regimen of bortezomib + cyclophosphamide + dexamethasone (VCD) | Guangdong General Hospital; Guangdong General Hospital, self-paying | type AL amyloidosis | | | | |
ChiCTR2000039966: The efficacy of Bortezomib with lenalidomide and dexamethasone (VRd) in newly diagnosised multiple myeloma and screening for associated biomarkers |
|
|
| Recruiting | 4 | 100 | | VRd regmen | Department of Hematology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, self-prepare capital | multiple myeloma | | | | |
NCT03908138: RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma |
|
|
| Recruiting | 4 | 120 | RoW | RDD, RDD group, VDD, VDD group | Shandong Provincial Hospital | Hematologic Neoplasms, Multiple Myeloma, Efficacy, Safety | 12/21 | 12/22 | | |
ChiCTR2000040808: A multicenter, prospective clinical study Induction therapy with Domestic bortezomib /lenalidomide /dexamethasone (BLD) regimen in newly diagnosed multiple myeloma patients |
|
|
| Recruiting | 4 | 100 | | bortezomib/lenalidomide/dexamethasone (BLD) | Shandong Cancer Hospital Affiliated to Shandong University; Shandong Cancer Hospital Affiliated to Shandong University, Self-funded | Multiple Myeloma | | | | |
ChiCTR2000035067: A multicentre, prospective, single arm study of bortezomib combined with glucocorticoid in the salvage treatment of relapsed / refractory acquired hemophilia A (AHA) |
|
|
| Recruiting | 4 | 20 | | bortezomib combined with glucocorticoid | Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology& Blood Disease Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, None | Relapsed / refractory acquired hemophilia A (AHA) | | | | |
NCT05137860: Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD |
|
|
| Recruiting | 4 | 56 | RoW | Bortezomib, Intervention Group | Hospital General de Mexico | Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease | 12/22 | 06/23 | | |
| Recruiting | 4 | 70 | RoW | Thalidomide, Bortezomib, Dexamethason, Cyclophosphamide | Guangdong Provincial People's Hospital | Immunoglobulin Light-Chain Amyloidosis | 01/23 | 06/23 | | |
ChiCTR2200058238: Multicenter real-world study of selinexor combined with DVd regimen in high-risk relapsed and refractory myeloma |
|
|
| Not yet recruiting | 4 | 35 | | Celinisol + CD38 McAb + bortezomib + dexamethasone | Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University, Beijing Dengfeng Talent Plan | relapsed and refractory myeloma | | | | |
ChiCTR2100049585: Efficacy, Safety and Population Pharmacokinetics of Bortezomib Combined with Chemotherapy in children with Refractory/Relapsed Acute Lymphoblastic Leukemia: a Multicenter, Randomized controlled Study |
|
|
| Recruiting | 4 | 132 | | Bortezomib ;no | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Shandong University | Childhood leukemia | | | | |
ChiCTR1900025577: A prospective, non-randomized clinical study for bortezomib, lenadomide/cyclophosphamide and dexamethasone in the treatment of primary multiple myeloma |
|
|
| Completed | 4 | 50 | | Bortezomib Combined with Dexamethasone and Lenalidomide ;Bortezomib combined with dexamethasone and cyclophosphamide | The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, Primary Health Care Foundation of China | Multiple Myeloma | | | | |
NCT05135442: Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP |
|
|
| Not yet recruiting | 4 | 30 | RoW | Bortezomib Injection, plasma exchange, hormone therapy | Peking Union Medical College Hospital | Thrombotic Thrombocytopenic Purpura, Acquired | 11/23 | 11/25 | | |
ChiCTR2200062860: A single-arm, open, observational clinical study of selinexor combined with bortezomib, lenalidomide, and dexamethasone in the treatment of newly diagnosed patients with extramedullary, plasma cell leukemia, or high-risk multiple myeloma |
|
|
| Recruiting | 4 | 40 | | Selinexor+bortezomib+lenalidomide + dexamethasone | Qingdao Municipal Hospital; Qingdao Municipal Hospital, none | multiple myeloma | | | | |
Real MM, NCT03829371: STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA |
|
|
| Recruiting | 4 | 450 | Europe | Velcade, Melphalan, Prednisone, Lenalidomide, Dexamethasone, Daratumumab | University of Turin, Italy | Multiple Myeloma | 01/25 | 01/30 | | |
ChiCTR2200058869: Efficacy of Zhima Qianzi Capsules in the treatment of bortezomib-induced peripheral neuropathy in patients with multiple myeloma: a self-controlled clinical trial |
|
|
| Not yet recruiting | 4 | 100 | | Zhima Qianzi Capsules | The First Affiliated Hospital of Zhejiang University of traditional Chinese Medicine; The First affiliated Hospital of Zhejiang Chinese Medical University, Self-financing | multiple myeloma | | | | |
ChiCTR2200059910: A prospective clinical study of bendamustine/pomalidomide/bortezomib/dexamethasone (BPVd) in the treatment of patients with relapsed and refractory multiple myeloma |
|
|
| Recruiting | 4 | 60 | | BDVP scheme | Department of Hematology, Second Affiliated Hospital of Anhui Medical University; The Second Affiliated Hospital of Anhui Medical University, Self-funded by the department | multiple myeloma | | | | |
ChiCTR2100049664: Bortezomib combined with chemotherapy in adults with relapsed/refractory acute lymphoblastic leukemia |
|
|
| Not yet recruiting | 4 | 20 | | Bortezomib | Jiaozuo People's Hospital; Jiaozuo People's Hospital, Beijing Medical Award Foundation | Adult Acute Lymphoblastic Leukemia | | | | |
ChiCTR1900023193: Study for the efficacy and safety of oral arsenic realgar-Indigo naturalis formula combined with VRD regimen in the treatment of primary multiple myeloma |
|
|
| Not yet recruiting | 4 | 184 | | VRD protocol (Bortezomib, Lenadomide, Dexamethasone) + RIF ;VRD protocol (Bortezomib, Lenadomide, Dexamethasone) | Huadong Hospital; Level of the institution：, self-finance | multiple myeloma | | | | |
ChiCTR2200058237: A multicenter, real-world study of selinexor and VRD regimen in the treatment of newly diagnosed high-risk multiple myeloma |
|
|
| Not yet recruiting | 4 | 35 | | Celinisol + bortezomib + lenalidomide + dexamethasone | Beijing Chaoyang Hospital, Capital Medical University; Beijing Chaoyang Hospital, Capital Medical University, Beijing Dengfeng Talent Plan | Multiple Myeloma | | | | |
ChiCTR2000031516: A clinical study on the maintenance strategy of multiple myeloma after autologous hematopoietic stem cell transplantation based on the detection of minimal residual disease |
|
|
| Not yet recruiting | 4 | 50 | | bortezomib/lenalidomide | The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, research funding | multiple myeloma | | | | |
ChiCTR2000038062: Prospective real-world study of ixazomib and lenalidomide-based continuous treatment after induction therapy with bortezomib, lenalidomide and dexamethasone (BRd) in newly diagnosed elderly multiple myeloma |
|
|
| Recruiting | 4 | 100 | | BRd+IRd+IR | The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Self-raised | Multiple Myeloma | | | | |
ChiCTR2000038075: Prospective real-world study of ixazomib and lenalidomide-based continuous treatment after induction therapy of bortezomib, lenalidomide and dexamethasone (BRd) with newly diagnosed young multiple myeloma |
|
|
| Recruiting | 4 | 150 | | BRd+/-ASCT+IRd+IR | The First Affiliated Hospital of Fujian Medical University; The First Affiliated Hospital of Fujian Medical University, Self-raised | Multiple Myeloma | | | | |
US MM-6, NCT03173092: A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM) |
|
|
| Active, not recruiting | 4 | 141 | US | Ixazomib, NINLARO, MLN9708, Lenalidomide, Dexamethasone | Takeda | Multiple Myeloma | 11/26 | 11/26 | | |
ChiCTR2200066618: Efficacy and Safety of DVD Regimen in the Newly Diagnosed Multiple Myeloma Patients with Renal Impairment:A Single-center Single-arm Prospective Clinical Trial |
|
|
| Not yet recruiting | 4 | 50 | | Bortezomib + pegylated liposomal doxorubicin (PLD) + Dexamethasone | The 2nd Affiliated Hospital of Harbin Medical University ; The 2nd Affiliated Hospital of Harbin Medical University, Beijing Lize Charity Foundation | Multiple Myeloma | | | | |
RESTORE, NCT06015750: Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia |
|
|
| Not yet recruiting | 4 | 8 | NA | methotrexate, rituximab, bortezomib, IVIg, Folic Acid | Alexion Pharmaceuticals, Inc. | Hypophosphatasia | 04/28 | 04/28 | | |
